-DOCSTART- -X- O
Human -X- _ O
immunotherapy -X- _ O
with -X- _ O
checkpoint -X- _ O
blockades -X- _ O
has -X- _ O
achieved -X- _ O
significant -X- _ O
breakthroughs -X- _ O
in -X- _ O
recent -X- _ O
years. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
a -X- _ O
checkpoint -X- _ B-Intervention
blockade -X- _ I-Intervention
vaccine -X- _ I-Intervention
for -X- _ O
canine -X- _ B-Patient
melanoma -X- _ I-Patient
was -X- _ O
tested -X- _ O
for -X- _ O
safety -X- _ O
and -X- _ O
immunogenicity. -X- _ O
Five -X- _ B-Patient
healthy -X- _ I-Patient
adult -X- _ I-Patient
dogs -X- _ I-Patient
received -X- _ O
a -X- _ O
mixture -X- _ O
of -X- _ O
three -X- _ O
replicationdefective -X- _ O
chimpanzee-derived -X- _ O
adenoviral -X- _ O
vectors -X- _ O
, -X- _ O
one -X- _ O
expressing -X- _ O
mouse -X- _ O
fibroblast-associated -X- _ O
protein -X- _ O
( -X- _ O
mFAP -X- _ O
) -X- _ O
and -X- _ O
the -X- _ O
others -X- _ O
expressing -X- _ O
canine -X- _ O
melanoma-associated -X- _ O
antigens -X- _ O
Trp-1 -X- _ O
or -X- _ O
Trp-2 -X- _ O
fused -X- _ O
into -X- _ O
Herpes -X- _ O
Simplex-1 -X- _ O
glycoprotein -X- _ O
D -X- _ O
, -X- _ O
a -X- _ O
checkpoint -X- _ O
inhibitor -X- _ O
of -X- _ O
herpes -X- _ O
virus -X- _ O
entry -X- _ O
mediator -X- _ O
( -X- _ O
HVEM -X- _ O
) -X- _ O
pathways. -X- _ O
The -X- _ O
vaccine -X- _ B-Outcome
mixture -X- _ I-Outcome
was -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
well -X- _ I-Outcome
tolerated -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
frequencies -X- _ I-Outcome
of -X- _ I-Outcome
canineTrp-1-specific -X- _ I-Outcome
activated -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
secreting -X- _ I-Outcome
interferon- -X- _ I-Outcome
( -X- _ I-Outcome
IFN -X- _ I-Outcome
) -X- _ I-Outcome
-γ -X- _ I-Outcome
, -X- _ I-Outcome
tumor -X- _ I-Outcome
necrosis -X- _ I-Outcome
factor -X- _ I-Outcome
( -X- _ I-Outcome
TNF -X- _ I-Outcome
) -X- _ I-Outcome
-α -X- _ I-Outcome
, -X- _ I-Outcome
or -X- _ I-Outcome
interleukin -X- _ I-Outcome
( -X- _ I-Outcome
IL -X- _ I-Outcome
) -X- _ I-Outcome
-2 -X- _ I-Outcome
alone -X- _ I-Outcome
or -X- _ I-Outcome
in -X- _ I-Outcome
combinations -X- _ I-Outcome
in -X- _ I-Outcome
four -X- _ I-Outcome
and -X- _ I-Outcome
five -X- _ I-Outcome
out -X- _ I-Outcome
of -X- _ I-Outcome
five -X- _ I-Outcome
dogs -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
To -X- _ I-Outcome
avoid -X- _ I-Outcome
excessive -X- _ I-Outcome
bleeds -X- _ I-Outcome
, -X- _ I-Outcome
responses -X- _ I-Outcome
to -X- _ I-Outcome
cTrp-2 -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
analyzed. -X- _ I-Outcome
All -X- _ I-Outcome
dogs -X- _ I-Outcome
responded -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
frequencies -X- _ I-Outcome
of -X- _ I-Outcome
mFAP-specific -X- _ I-Outcome
activated -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cells. -X- _ I-Outcome
The -X- _ O
results -X- _ O
of -X- _ O
this -X- _ O
safety -X- _ O
/ -X- _ O
immunogenicity -X- _ O
trial -X- _ O
invite -X- _ O
further -X- _ O
testing -X- _ O
of -X- _ O
this -X- _ O
checkpoint -X- _ O
blockade -X- _ O
vaccine -X- _ O
combination -X- _ O
in -X- _ O
dogs -X- _ O
with -X- _ O
melanoma. -X- _ O
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
10.1007 -X- _ O
/ -X- _ O
s00262-018-2201-5 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

